# Molecular Axiom

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molecular-axiom

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series A (Dec 14, 2022)
- Investors on record: 3

## About

Based in Shanghai, China, and established in 2022, Molecular Axiom is a biotechnology company that focuses on the R&D of nucleic acid drugs for cancers. Dr. Bohan Le, the company's co-founder, is a serial entrepreneur, who co-established Fronthera Pharmaceuticals, and three projects of Fronthera Pharmaceuticals entered the clinical phase, and one drug sold USD 180 million to Foresite Capital in March 2021. Dr. Lishan Chen, the company's co-founder, established the nucleic drugs R&D platform, and the R&D of nucleic acid drug delivery technologies. 

Molecular Axiom engages in the R&D of nucleic acid drugs for central nervous system diseases, lung diseases, and skin diseases. It also focuses on nucleic acid drug delivery technologies. And it developed nucleic acid drug inhalation delivery technology for cancers and inflammatory diseases.

## Funding rounds

- Series A, Dec 14, 2022 — GP Capital, Oriental Fortune Capital, Realharmony Capital

## Investors

- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series A
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- Realharmony Capital (https://capitalatlas.ai/funds/realharmony-capital) — Series A